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(57) 	 ABSTRACT 
The present invention provides a method of producing a pla-
nar lipid bilayer on a solid support. With this method, a 
solution of lipid vesicles is first deposited on the solid sup-
port. Next, the lipid vesicles are destabilized by adding an 
amphipathic peptide solution to the lipid vesicle solution. 
This destabilization leads to production of a planar lipid 
bilayer on the solid support. The present invention also pro-
vides a supported planar lipid bilayer, where the planar lipid 
bilayer is made of naturally occurring lipids and the solid 
support is made of unmodified gold or titanium oxide. Pref-
erably, the supported planar lipid bilayer is continuous. The 
planar lipid bilayer may be made of any naturally occurring 
lipid or mixture of lipids, including, but not limited to phos-
phatidylcholine, phosphatidylethanolamine, phosphati-
dylserine, phosphatidylinsitol, cardiolipin, cholesterol, and 
sphingomyelin. 
4 Claims, 4 Drawing Sheets 
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METHOD OF FABRICATING LIPID BILAYER 
MEMBRANES ON SOLID SUPPORTS 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application is a national stage filing under 35 U.S.C. 
§371 of International Patent Application Ser. No. PCT/ 
US2006/012085, which was filed on Mar. 29, 2006 and which 
was published in English under PCT Article 21(2) as WO 
2006/110350 on Oct. 19, 2006, which International Patent 
Application claims benefit of priority of U.S. Provisional 
Patent Application Ser. No. 60/666,647, filed Mar. 29, 2005, 
which applications are incorporated herein by reference in 
their entirety. 
FEDERALLY-SPONSORED RESEARCH OR 
DEVELOPMENT 
2 
solution of lipid vesicles is first deposited on the solid sup-
port. Next, the lipid vesicles are destabilized by adding an 
amphipathic peptide solution to the lipid vesicle solution. 
This destabilization leads to production of a planar lipid 
5 bilayer on the solid support. Preferably, the amphipathic pep-
tide is an alpha-helical peptide. More preferably, the alpha-
helical peptide is a polypeptide having the entirety or a por-
tion of the sequence SEQ ID NO: 1. 
The present invention also provides a supported planar 
10 lipid bilayer, where the planar lipid bilayer is made of natu-
rally occurring lipids and the solid support is made of 
unmodified gold or titanium oxide. Preferably, the supported 
planar lipid bilayer is continuous. The planar lipid bilayer 
may be made of any naturally occurring lipid or mixture of 
15 lipids, including but not limited to phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylserine, phosphati-
dylinositol, cardiolipin, cholesterol, and sphingomyelin. 
This invention was made with Government support under 
contracts NAG-8-1843 awarded by the NASA Marshall 
Space Flight Center and 0213618 awarded by the National 
Science Foundation. The Government has certain rights in 
this invention. 
FIELD OF THE INVENTION 
The present invention relates generally to lipid mem-
branes. More particularly, the present invention relates to 
methods of fabricating lipid bilayer membranes on solid sup-
ports. 
BACKGROUND 
Supported lipid bilayers formed by the fusion of small 
unilamellar vesicles onto silicon oxide or organic film-modi-
lied surfaces enable the biofunctionalization of inorganic sol-
ids, such as semiconductors, gold-covered surfaces, and opto-
electronic and lab-on-a-chip devices. They have proven 
valuable in the study of the characteristics and behavior of 
membrane-bound proteins, membrane-mediated cellular 
processes, protein-lipid interactions, and biological signal 
transduction. Because of the complexity of biomembranes, 
there is a clear need to develop model membrane systems, 
where one or a few membrane components can be isolated 
and studied. In addition, a wide range of available surface-
sensitive techniques can be used to study natural biological 
systems effectively by supporting model membranes on a 
solid surface. Applications of supported membranes on solid 
surfaces potentially include biosensors, programmed drug 
delivery, the acceleration and improvement of medical 
implant acceptance, and the production of catalytic inter-
faces. 
In order to mimic natural biological systems, researchers 
have employed vesicle fusion methods to form supported 
bilayers on substrates such as glass, mica, self-assembled 
monolayers, and quartz. However, it has proven problematic 
to create planar lipid bilayers on preferred solid substrates, 
such as gold and Ti02 . For example, scientists have attempted 
to modify gold surfaces using self-assembled monolayers 
(SAMs), which may require special synthesis, but the struc-
ture of the SAMs that are formed may not be well-defined. 
Accordingly, there is a need in the art to develop new methods 
of forming supported bilayers on preferred substrates. 
SUMMARY OF THE INVENTION 
The present invention provides a method of producing a 
planar lipid bilayer on a solid support. With this method, a 
BRIEF DESCRIPTION OF THE FIGURES 
20 
The present invention together with its objectives and 
advantages will be understood by reading the following 
description in conjunction with the drawings, in which: 
FIG. 1 shows a method of producing a planar lipid bilayer 
25 according to the present invention. 
FIG. 2 shows quartz crystal microbalance-dissipation 
(QCM-D) analysis of planar lipid bilayer formation on a gold 
substrate according to the present invention. 
FIG. 3 shows QCM-D analysis of planar lipid bilayer for- 
30 mation on a Ti0 2 substrate according to the present invention. 
FIG. 4 shows atomic force microscopy (AFM) analysis of 
planar lipid bilayer formation on a Ti0 2 substrate according 
to the present invention. 
35 DETAILED DESCRIPTION OF THE INVENTION 
FIG.1 illustrates a schematic of a method according to the 
present invention. FIG. 1A shows lipid vesicles 110 that have 
been deposited onto solid substrate 120. The vesicles have 
4o adsorbed to solid substrate 120. A large amount of water, 
indicated by circles 130, is trapped within the intact vesicles 
as well as between vesicles adsorbed on the surface of solid 
substrate 120. After addition of an amphipathic peptide (AP) 
solution (FIG. 113), the vesicles are destabilized and ruptured, 
45 allowing the ruptured vesicles to fuse and form planar bilayer 
112. When planar bilayer 112 forms, water 130 trapped 
within vesicles 112 is dispersed to form water layer 132. 
The amphipathic peptide is preferably an alpha-helical 
peptide. More preferably, the amphipathic peptide is the AH 
50 peptide of the HCV nonstructural protein NS5A. This peptide 
is conserved across HCV isolates and has the sequence SEQ 
ID NO: 1. Either the entire peptide, amino acids 1-16 of the 
peptide (AH_SI), or amino acids 17-31 of the peptide 
(AH_S2) may be used to destabilize the lipid vesicles. Alter- 
55 natively, the peptide may not have the exact sequence of SEQ 
ID NO: 1, as long as its amphipathic alpha-helical nature is 
preserved. For example, as shown by circular dichroism, the 
peptide may have a sequence that is at least about 80% iden-
tical to SEQ ID NO: 1, while still maintaining alpha-helicity. 
60 Preferably, the concentration of amphipathic peptide in the 
peptide solution is between about 0.05 µg/ml to 0.5 µg/ml. 
The amphipathic peptide may be contained in a variety of 
solvents, including biological buffers (such as Tris buffer, 
PBS buffer, and HEPES Buffer) and dimethylsulfoxide 
65 (DMSO). 
Lipid vesicles suitable for the present invention are prefer-
ably between about 25 nm and about 80 nm in diameter. The 
US 8,211,712 B2 
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vesicles may be prepared using any method known in the art, 
including but not limited to extrusion methods. The vesicles 
are preferably at a concentration of about 0.05 mg/ml to about 
5 mg/ml in a biological buffer, such as Tris, PBS, and HEPES 
buffer, with NaCl concentration of about 100 mM to about 
250 mM. Any lipid or mixture of lipids may be used to form 
the lipid vesicles, including but not limited to phospholipids. 
Preferred lipids are phosphatidylcholine, phosphatidyletha-
nolamine, phosphatidylserine, phosphatidylinositol, cardio-
lipin, cholesterol, and sphingomyelin. 
Any solid support may be used according to the present 
invention. Example materials include, but are not limited to 
silicon-containing materials, gold, platinum, and titanium 
oxide. 
The present invention also provides supported planar lipid 
bilayers produced using the method of the present invention. 
Preferably, the lipid bilayer is composed of naturally occur-
ring lipids andthe solid support is made of unmodified gold or 
titanium oxide. Any naturally occurring lipid may be used for 
the bilayer, such as phospholipids. Preferred lipids are phos-
phatidylcholine, phosphatidylethanolamine, phosphati-
dylserine, phosphatidylinositol, cardiolipin, cholesterol, and 
sphingomyelin. Preferably, planar lipid bilayers according to 
the present invention are continuous, i.e. there are no gaps in 
the layer. 
EXAMPLES 
Formation of a Planar Lipid Bilayer on a Sold Substrate 
Bilayer formation from intact vesicles was characterized 
using a quartz crystal microbalance-dissipation (QCM-D) 
instrument. To interpret the QCM-D results, a linear relation-
ship between Af and adsorbed mass (Am) derived from the 
classical Sauerbrey equation was employed: 
C Equation (1) 
Om = 
--Of 
n 
where C is the mass-sensitivity constant with value 17.7 
ngcrn 2Hz i for the QCM-D crystal at 5 MHz, and n is the 
overtone number (n=1 for the fundamental and 3, 5, 7 for the 
overtones). The QCM-D has been used in numerous studies 
of the vesicle fusion process, where the dissipation is used to 
distinguish between rigid lipid bilayers and monolayers and 
soft deformable vesicles (see, e.g., Keller and Kasemo, "Sur-
face specific kinetics of lipid vesicle adsorption measured 
with a quartz crystal microbalance", Biophys J. 1998 Sep; 
75(3):1397-1402). 
In order to investigate the ability of AH peptides to rupture 
vesicles, we tested unilamellar vesicles of 1-palmitoyl-2-ole-
oyl-sn-glycero-3-phosphocholine (POPC) extruded through 
30 mu polycarbonate etch-tracked (PEC) membranes on a 
gold surface in the absence of theAH peptide, then applied the 
peptide to form a bilayer. When vesicles adsorb, a large 
amount of trapped water exists within the intact vesicles as 
well as between vesicles adsorbed on the surface. This 
trapped water is able to dissipate a large amount of energy, 
unlike the water that rests on top of a bilayer. This change in 
energy dissipation can in turn be used to track the transition 
between an intact vesicle and a bilayer. 
In FIG. 2, Af(t) (triangles) and AD(t) (circles) show change 
in frequency and change in dissipation. FIG. 2A shows 
vesicle adsorption on an oxidized gold surface. After 10 min 
(arrow 1) of stabilizing the frequency signal, the POPC 
vesicle solution (0.1 mg/ml, O3onm ,c-59 nm ±0.2 mu) was 
4 
injected into a liquid cell. After 50 and 55 min (arrows 2 and 
3), the same buffer that was used to dilute the vesicles (10 mM 
Tris (pH 7.5), 150 mM NaCl solution with 1 mM EDTA in 
18.2 MQ-cm MilliQ water (MilliPore, Oreg., USA) was used 
5 to wash the substrate twice and the stability of the intact 
vesicles on the gold surface was observed. As shown in FIG. 
213, at 60 min (arrow 4), an amphipathic_-helix peptide (AH 
peptide) solution was added (0.05 µg/ml) to the intact vesicles 
(031nm PEC 59 nm ±0.2 mu) on the gold surface. The peptide 
io destabilized and ruptured the vesicles, making a complete 
bilayer. This is reflected in a decrease of frequency of 25.5 Hz 
±0.5, with a maximum decrease of dissipation of as much as 
0.08x10-6 observed. After 120 and 140 min (arrows 5 and 6), 
the vesicle bufferwas used to wash the substrate twice and the 
15 stability of the bilayers on the gold surface was observed. 
According to the Sauerbrey equation, from which the bilayer 
thickness can be calculated, these QCM-D parameters indi-
cate the transition of the vesicles to a thin and rigid bilayer 
film. 
20 	 In FIG. 2C, the effect of a non-amphipathic non-helical 
peptide (NH peptide) was examined. Unlike the AH peptide, 
the NH peptide has three charged amino acids spaced at 
intervals along the predicted N-terminal helix such that no 
sustained hydrophobic patch remains. The NH peptide has an 
25 Asp rather than a Val at residue 8, a Glu instead of an IIe at 
residue 12, and an Asp instead of a Phe at residue 19 of SEQ 
ID NO: 1. In FIG. 2C, after 10 nm (arrow 1) of stabilizing the 
frequency signal, the POPC vesicle solution (0.1 mg/ml, 
031nm ,C59 mn ±0.2 nm) was applied to the liquid cell. 
3o After 60 and 70 min (arrows 2 and 3), the vesicle buffer was 
used to wash the substrate twice and the stability of the intact 
vesicles on the gold surface was observed. At 85 min (arrow 
4), the NH peptide solution was added (0.05 µg/ml) to the 
intact vesicles on the gold surface. The NH peptide does not 
35 show any evidence of having destabilized and ruptured the 
vesicles. After 160 min (arrow 5), the vesicle buffer was used 
to wash the substrate twice and the stability of the intact 
vesicles on the gold surface was observed. 
Formation of a Planar Lipid Bilayer on a TiO 2 Substrate 
40 In order to investigate the ability of AH peptides to rupture 
vesicles on a TiO2 surface, we tested unilamellar vesicles of 
POPC extruded through 30 nm PEC membranes on a TiO 2 
surface in the absence of the AH peptide, then applied the 
peptide to form a bilayer (FIG. 3). In FIG. 3, Af(t) (triangles) 
45 and AD(t) (circles) show change in frequency and change in 
dissipation. FIG. 3A shows vesicle adsorption on a TiO 2 
surface. After 10 min (arrow 1) of stabilizing the frequency 
signal, the POPC vesicle solution (0.1 rag/ml, 031min  P,c-59 
nm ±0.2 mu) was injected into the liquid cell. After 60 and 65 
50 min (arrows 2 and 3), the same buffer that was used to dilute 
the vesicles (10 mM Tris (pH 7.5); 150 mM NaCl solution 
with 1 mM EDTA in 18.2 MQ-cm MilliQ water (MilliPore, 
Oreg., USA) was used to wash the substrate twice and the 
stability of the intact vesicles on the TiO 2 surface was 
55 observed. As shown in FIG. 313, at 70 min (arrow 4), the AH 
peptide solution was added (0.05 µg/ml) to the intact vesicles 
(O31nm ,C59 nm ±0.2 nm) on the TiO2 surface (FIG. 213). 
The peptide destabilized and ruptured the vesicles, making a 
complete bilayer. After 270 min (arrow 5), the vesicle buffer 
60 was used to wash the substrate twice and the stability of the 
bilayers on the TiO2 surface was observed. 
In FIG. 3C, the effect of the NH peptide was examined. In 
FIG. 3C, after 10 min (arrow 1) of stabilizing the frequency 
signal, the POPC vesicle solution (0.1 mg/ml, 031nm P,c-59 
65 nm ±0.2 nm) was applied to the liquid cell. After 40 and 50 
min (arrows 2 and 3), the vesicle buffer was used to wash the 
substrate twice and the stability of the intact vesicles on the 
US 8,211,712 B2 
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Ti02 surface was observed. At 60 min (arrow 4), the NH 
peptide solution was added (0.05 µg/ml) to the intact vesicles 
on the Ti02 surface. The NH peptide does not show any 
evidence of having destabilized and ruptured the vesicles. 
After 270 min (arrow 5), the vesicle buffer was used to wash 
the substrate twice and the stability of the intact vesicles on 
the Ti02 surface was observed. 
6 
the AH peptides ruptured vesicles to form bilayers (P 
X0.001). These results correlate with QCM-D kinetic data. 
As one of ordinary skill in the art will appreciate, various 
changes, substitutions, and alterations could be made or oth-
erwise implemented without departing from the principles of 
the present invention. Accordingly, the scope of the invention 
should be determined by the following claims and their legal 
equivalents. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 1 
<210> SEQ ID NO 1 
<211> LENGTH: 31 
<212> TYPE: PRT 
<213> ORGANISM: Hepatitis C virus 
<400> SEQUENCE: 1 
Ser Gly Ser Trp Leu Arg Asp Val Trp Asp Trp Ile Cys Thr Val Leu 
1 	 5 	 10 	 15 
Thr Asp Phe Lys Thr Trp Leu Gin Ser Lys Leu Asp Tyr Lys Asp 
20 	 25 	 30 
AFM Analysis of Lipid Bilayer Formation According to 
the Present Invention 
AFM was utilized in order to confirm and directly display 
rupture of vesicles and bilayer formation by the destabilizing 
agent the AH peptide. FIG. 4 shows the results of this analy-
sis. For each column, the top image shows a top view in 2-1), 
the middle image shows a top view in 3-1), and the graph 
shows measurements taken along the black line shown in the 
top image. The images are presented in Height mode. Scans 
were taken in the direction indicated by the white arrow on 
FIG. 4A, top image. 
In FIG. 4A, AFM was conducted on a bare Ti0 2 surface in 
Tris buffer (150 mM NaCl, 10 mM Tris [pH 7.5], 1 mM 
EDTA) as a control. The bare Ti0 2 surface showed an average 
root mean square roughness (Rq) of 1.63 ±0.12 nm (±S.E. 
n=15). 59 mu ±0.2 mu diameter POPC vesicles (0.1 mg/ml) 
were carefully added through the injection system, incubated 
for 30 minutes, and thoroughly rinsed three times with Tris 
buffer. Intact vesicles. such as vesicle 410, were clearly iden-
tified by AFM and the average Rq increased to 2.70 ±0.15 mu 
(±S.E. n=15), as shown in FIG. 413. A grain analysis was 
applied in order to identify and count the vesicles. In order to 
minimize the effects of particles other than vesicles, only 
diameters between 50 to 100 nm hyperbolar-shaped objects 
were counted. The AFM images, as shown in FIG. 413, and 
grain analysis were used to identify the sizes of thirteen 
vesicles. The vesicles had an average diameter of 74.57 ±4.07 
mu (±S.E. n=13) and average volume of 3.32x10-5 µm 3 
±6.16x10-6 µm3 (±S.E. n=13). Cross-sectional analysis dis-
plays the height of the vesicles to be approximately 15 mu. 
The AFM images in FIG. 4C show the effect of the AH 
peptide on the vesicles as a destabilizing agent, which was 
examined by injecting the peptide (0.05 µg/ml) and incubat-
ing the solution for 2 hours prior to scanning the images. 
These images clearly confirm the QCM-D data, indicating 
that vesicles were ruptured as a result of the treatment by AH 
peptide at 0.05 µg/ml concentration after 120 minutes. The 
average Rq of 1.67 ±0.12 nm (±S.E. n=15) indicated the 
roughness became similar to the bare Ti0 2 surface. Grain 
analysis identified no vesicle-like structures, indicating that 
What is claimed is: 
1. A supported planar lipid bilayer comprising: 
a) a planar lipid bilayer comprising naturally occurring 
30 	 lipids; and 
b) a solid support comprising unmodified gold or titanium 
oxide; 
wherein said lipid bilayer is supported by said solid sup-
port. 
35 	 2. The supported planar lipid bilayer as set forth in claim 1, 
wherein said lipids are phospholipids. 
3. The supported planar lipid bilayer as set forth in claim 1, 
wherein said lipids are selected from the group consisting of 
phosphatidylcholine, phosphatidylethanolamine, phosphati- 
4o dylserine, phosphatidylinositol, cardiolipin, cholesterol, and 
sphingomyelin. 
4. The supported planar lipid bilayer as set forth in claim 1, 
wherein said planar lipid bilayer is continuous. 
45 	 * * * * * 
50 
55 
60 
65 
